Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>GSK has reported a solid performance for Q3, demonstrating resilience amid market challenges, and importantly, provides insights into its strategic direction and immediate financial health.</li><li>For the third quarter, GSK reported a 9% sales growth year-to-date and a 19% profit growth.</li><li>This growth primarily stems from the acceleration in Specialty Medicines which underscores GSK’s strategic shift towards high margin areas.</li></ul>

GSK has reported a solid performance for Q3, demonstrating resilience amid market challenges, and importantly, provides insights into its strategic direction and immediate financial health.For the third quarter, GSK reported a 9% sales growth year-to-date and a 19% profit growth.This growth primarily stems from the acceleration in Specialty Medicines which underscores GSK’s strategic shift towards high margin areas.

GlaxoSmithKline (GSK): Will The Acquisition of Novel Lupus Therapy from Chimagen Be A Game Changer? - Major Drivers

APAC IPOs & Placements, Aequitas Research

Clarence Chu

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/indegene-limited" target="_blank" data-smartkarma-citation="entities:36629:1" rel="noopener">Indegene Limited (1864095D IN)</a> was listed in India on 13th May 2024 after raising US$221m. Its six-month lockup will expire on 5th Nov 2024. </li>
<li>Indegene is a “digital-first” commercialisation firm with an exclusive focus on the global life sciences industry.</li>
<li>In this note, we will talk about the lock-up dynamics and updates since our last note.</li>
</ul>



Indegene Limited (1864095D IN) was listed in India on 13th May 2024 after raising US$221m. Its six-month lockup will expire on 5th Nov 2024. 
Indegene is a “digital-first” commercialisation firm with an exclusive focus on the global life sciences industry.
In this note, we will talk about the lock-up dynamics and updates since our last note.


Indegene Lockup Expiry - US$1bn+ Lockup Release, Some Could Look to Book 3x Gain

<ul><li>GSK has reported a strong performance for its second quarter of the year, with a 13% increase in sales to GBP 7.9 billion.</li><li>Highlighting the company's effective operational execution and a diverse portfolio, GSK's core operating profit improved by 21% to GBP 2.5 billion, and core earnings per share increased by 17% to 43.4p, all figures adjusted to exclude contributions from COVID solutions.</li><li>This demonstrates GSK's ability to achieve profitable growth driven by both its longstanding and newly launched products.</li></ul>

GSK has reported a strong performance for its second quarter of the year, with a 13% increase in sales to GBP 7.9 billion.Highlighting the company's effective operational execution and a diverse portfolio, GSK's core operating profit improved by 21% to GBP 2.5 billion, and core earnings per share increased by 17% to 43.4p, all figures adjusted to exclude contributions from COVID solutions.This demonstrates GSK's ability to achieve profitable growth driven by both its longstanding and newly launched products.

GlaxoSmithKline plc: Will Its Enhanced Focus on Immunotherapy and Oncology Yield Dividends? - Major Drivers

<ul><li>GSK's recent quarterly report underlines a robust upward trajectory with significant growth figures, showcasing the strength and diversity of its product portfolio in pharmaceuticals and healthcare.</li><li>The company reported a 13% growth in sales to GBP 7.9 billion and a 21% increase in core operating profit to GBP 2.5 billion.</li><li>Core earnings per share also rose by 17% to 43.4p, excluding COVID solutions.</li></ul>

GSK's recent quarterly report underlines a robust upward trajectory with significant growth figures, showcasing the strength and diversity of its product portfolio in pharmaceuticals and healthcare.The company reported a 13% growth in sales to GBP 7.9 billion and a 21% increase in core operating profit to GBP 2.5 billion.Core earnings per share also rose by 17% to 43.4p, excluding COVID solutions.

GlaxoSmithKline plc: Enhancing Market Position with AREXVY and Other Major Brands! - Major Drivers

<ul><li>GSK has reported a robust start to the year with notable growth in both sales and profits, driven by strong execution and successful product launches.</li><li>Total sales increased by 13% to GBP 7.4 billion, with core operating profit surging by 35% to GBP 2.4 billion, and core earnings per share growing by 37% to 43.1p.</li><li>These figures exclude contributions from COVID solutions, underscoring the company's success in its core operations.</li></ul>

GSK has reported a robust start to the year with notable growth in both sales and profits, driven by strong execution and successful product launches.Total sales increased by 13% to GBP 7.4 billion, with core operating profit surging by 35% to GBP 2.4 billion, and core earnings per share growing by 37% to 43.1p.These figures exclude contributions from COVID solutions, underscoring the company's success in its core operations.

GlaxoSmithKline plc (GSK): What Is The Development In Terms Of Pipeline Development & Recent Technological Advancements? - Major Drivers

United States

GSK PLC operates as a research-based pharmaceutical company. The Company develops, manufactures, and markets vaccines, prescription, and over-the-counter medicines, as well as health-related consumer products. GSK provides products for infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

GSK (GSK US)

GlaxoSmithKline (GSK): Will The Acquisition of Novel Lupus Therapy from Chimagen Be A Game Changer? - Major Drivers

GSK has reported a solid performance for Q3, demonstrating resilience amid market challenges, and importantly, provides insights into its...

Baptista Research

Indegene Lockup Expiry - US$1bn+ Lockup Release, Some Could Look to Book 3x Gain

Indegene Limited (1864095D IN) was listed in India on 13th May 2024 after raising US$221m. Its six-month lockup will expire on 5th Nov 2024.

Clarence Chu

GlaxoSmithKline plc: Will Its Enhanced Focus on Immunotherapy and Oncology Yield Dividends? - Major Drivers

GSK has reported a strong performance for its second quarter of the year, with a 13% increase in sales to GBP 7.9 billion. Highlighting the...

Baptista Research

GlaxoSmithKline plc: Enhancing Market Position with AREXVY and Other Major Brands! - Major Drivers

GSK's recent quarterly report underlines a robust upward trajectory with significant growth figures, showcasing the strength and diversity of its...

Baptista Research

GlaxoSmithKline plc (GSK): What Is The Development In Terms Of Pipeline Development & Recent Technological Advancements? - Major Drivers

GSK has reported a robust start to the year with notable growth in both sales and profits, driven by strong execution and successful product...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)